Atara Biotherapeutics Stock (NASDAQ:ATRA)


Chart

Previous Close

$8.25

52W Range

$5.00 - $18.70

50D Avg

$7.77

200D Avg

$8.81

Market Cap

$57.53M

Avg Vol (3M)

$55.21K

Beta

0.18

Div Yield

-

ATRA Company Profile


Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

153

IPO Date

Oct 16, 2014

Website

ATRA Performance


Latest Earnings Call Transcripts


Q2 22Aug 08, 22 | 7:32 PM
Q1 22May 05, 22 | 8:16 PM
Q4 21Feb 28, 22 | 10:49 PM

Peer Comparison


TickerCompany
ALLOAllogene Therapeutics, Inc.
MGNXMacroGenics, Inc.
HRTXHeron Therapeutics, Inc.
SGMOSangamo Therapeutics, Inc.
CTMXCytomX Therapeutics, Inc.
ANABAnaptysBio, Inc.